Enterococcus Faecium Infections - Pipeline Review, H1 2015

Published: May, 2015 | Pages: 131 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Enterococcus Faecium Infections - Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Enterococcus Faecium Infections - Pipeline Review, H1 2015', provides an overview of the Enterococcus Faecium Infections's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Enterococcus Faecium Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Enterococcus Faecium Infections and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Enterococcus Faecium Infections
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Enterococcus Faecium Infections and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Enterococcus Faecium Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Enterococcus Faecium Infections pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Enterococcus Faecium Infections
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Enterococcus Faecium Infections pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Enterococcus Faecium Infections Overview 10
Therapeutics Development 11
Pipeline Products for Enterococcus Faecium Infections - Overview 11
Pipeline Products for Enterococcus Faecium Infections - Comparative Analysis 12
Enterococcus Faecium Infections - Therapeutics under Development by Companies 13
Enterococcus Faecium Infections - Therapeutics under Investigation by Universities/Institutes 15
Enterococcus Faecium Infections - Pipeline Products Glance 16
Clinical Stage Products 16
Early Stage Products 17
Enterococcus Faecium Infections - Products under Development by Companies 18
Enterococcus Faecium Infections - Products under Investigation by Universities/Institutes 21
Enterococcus Faecium Infections - Companies Involved in Therapeutics Development 22
Alchemia Limited 22
Alvogen, Inc. 23
Aphios Corporation 24
Cellceutix Corporation 25
ConjuGon, Inc. 26
ContraFect Corporation 27
Enanta Pharmaceuticals, Inc. 28
Helix BioMedix, Inc. 29
LegoChem Biosciences, Inc 30
Lytix Biopharma AS 31
Melinta Therapeutics, Inc 32
MGB Biopharma Limited 33
Microbiotix, Inc. 34
MicuRx Pharmaceuticals, Inc. 35
Nabriva Therapeutics AG 36
NovaBay Pharmaceuticals, Inc. 37
Novan, Inc. 38
NovoBiotic Pharmaceuticals, LLC 39
Omnia Molecular Ltd. 40
Oragenics, Inc. 41
Sealife PHARMA GMBH 42
Sentinella Pharmaceuticals, Inc. 43
Sumitomo Dainippon Pharma Co., Ltd. 44
TAXIS Pharmaceuticals, Inc. 45
Wockhardt Limited 46
Enterococcus Faecium Infections - Therapeutics Assessment 47
Assessment by Monotherapy Products 47
Assessment by Target 48
Assessment by Mechanism of Action 50
Assessment by Route of Administration 52
Assessment by Molecule Type 54
Drug Profiles 56
auriclosene - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
brilacidin tetrahydrochloride - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
CF-304 - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
chrysophaentin - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
closthioamide - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
EDP-788 - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
Epimerox - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
GP-505 - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
HB-1345 - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
HT-01 - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
HT-02 - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
IBN-1 - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
LCB-010371 - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
LCB-010699 - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
lefamulin - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
LTX-109 - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
Marinus - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
MBX-1162 - Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
MGBBP-3 - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
MRX-I - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
MU-1140 - Drug Profile 82
Product Description 82
Mechanism of Action 82
R&D Progress 82
NAI-107 - Drug Profile 84
Product Description 84
Mechanism of Action 84
R&D Progress 84
NAI-603 - Drug Profile 86
Product Description 86
Mechanism of Action 86
R&D Progress 86
NVN-1000 - Drug Profile 87
Product Description 87
Mechanism of Action 87
R&D Progress 87
NVN-4428 - Drug Profile 88
Product Description 88
Mechanism of Action 88
R&D Progress 88
RX-05 - Drug Profile 89
Product Description 89
Mechanism of Action 89
R&D Progress 89
RXP-873 - Drug Profile 90
Product Description 90
Mechanism of Action 90
R&D Progress 90
SLP-0904 - Drug Profile 91
Product Description 91
Mechanism of Action 91
R&D Progress 91
SLP-0905 - Drug Profile 92
Product Description 92
Mechanism of Action 92
R&D Progress 92
SM-295291 - Drug Profile 93
Product Description 93
Mechanism of Action 93
R&D Progress 93
SM-369926 - Drug Profile 94
Product Description 94
Mechanism of Action 94
R&D Progress 94
Small Molecule for Bacterial Infections - Drug Profile 95
Product Description 95
Mechanism of Action 95
R&D Progress 95
Small Molecules for MRSA and Vancomycin-Resistant Enterococcus Faecium Infections - Drug Profile 96
Product Description 96
Mechanism of Action 96
R&D Progress 96
Small Molecules to Inhibit FtsZ Protein for MRSA and VRE Infections - Drug Profile 97
Product Description 97
Mechanism of Action 97
R&D Progress 97
Small Molecules to Inhibit Oxacillinase for Gram-Positive Bacterial Infections - Drug Profile 98
Product Description 98
Mechanism of Action 98
R&D Progress 98
Small Molecules to Inhibit Tryptophanyl-tRNA synthetase for Bacterial Infections - Drug Profile 99
Product Description 99
Mechanism of Action 99
R&D Progress 99
SP-2078 - Drug Profile 100
Product Description 100
Mechanism of Action 100
R&D Progress 100
Teixobactin - Drug Profile 102
Product Description 102
Mechanism of Action 102
R&D Progress 102
TXA-709 - Drug Profile 104
Product Description 104
Mechanism of Action 104
R&D Progress 104
WCK-4086 - Drug Profile 105
Product Description 105
Mechanism of Action 105
R&D Progress 105
Enterococcus Faecium Infections - Recent Pipeline Updates 106
Enterococcus Faecium Infections - Dormant Projects 124
Enterococcus Faecium Infections - Discontinued Products 126
Enterococcus Faecium Infections - Product Development Milestones 127
Featured News & Press Releases 127
Feb 25, 2015: MicuRx Initiates U.S. Phase 2 Clinical Trial For Novel Antibiotic MRX-I 127
Aug 26, 2013: Oragenics Collaboration Demonstrates Initial Success in the Second Phase of Lantibiotics Project 127
Feb 12, 2013: Oragenics-Intrexon Collaboration Announces Significant Progress Towards Commercial Production of Lead Lantibiotic MU1140 128
Sep 12, 2012: NovaBay Pharma Announces Data From New Study Demonstrating Chemical Impact Of N-chlorotaurine And NVC-422 On Bacterial Toxins 128
May 23, 2012: MicuRx Announces Issuance Of US Patent For Next-Generation Antibacterial Agent 129
Apr 23, 2012: MicuRx Completes Phase I Trial For MRX-I 129
Appendix 130
Methodology 130
Coverage 130
Secondary Research 130
Primary Research 130
Expert Panel Validation 130
Contact Us 130
Disclaimer 131

List of Tables

Number of Products under Development for Enterococcus Faecium Infections, H1 2015 11
Number of Products under Development for Enterococcus Faecium Infections - Comparative Analysis, H1 2015 12
Number of Products under Development by Companies, H1 2015 13
Number of Products under Development by Companies, H1 2015 (Contd..1) 14
Number of Products under Investigation by Universities/Institutes, H1 2015 15
Comparative Analysis by Clinical Stage Development, H1 2015 16
Comparative Analysis by Early Stage Development, H1 2015 17
Products under Development by Companies, H1 2015 18
Products under Development by Companies, H1 2015 (Contd..1) 19
Products under Development by Companies, H1 2015 (Contd..2) 20
Products under Investigation by Universities/Institutes, H1 2015 21
Enterococcus Faecium Infections - Pipeline by Alchemia Limited, H1 2015 22
Enterococcus Faecium Infections - Pipeline by Alvogen, Inc., H1 2015 23
Enterococcus Faecium Infections - Pipeline by Aphios Corporation, H1 2015 24
Enterococcus Faecium Infections - Pipeline by Cellceutix Corporation, H1 2015 25
Enterococcus Faecium Infections - Pipeline by ConjuGon, Inc., H1 2015 26
Enterococcus Faecium Infections - Pipeline by ContraFect Corporation, H1 2015 27
Enterococcus Faecium Infections - Pipeline by Enanta Pharmaceuticals, Inc., H1 2015 28
Enterococcus Faecium Infections - Pipeline by Helix BioMedix, Inc., H1 2015 29
Enterococcus Faecium Infections - Pipeline by LegoChem Biosciences, Inc, H1 2015 30
Enterococcus Faecium Infections - Pipeline by Lytix Biopharma AS, H1 2015 31
Enterococcus Faecium Infections - Pipeline by Melinta Therapeutics, Inc, H1 2015 32
Enterococcus Faecium Infections - Pipeline by MGB Biopharma Limited, H1 2015 33
Enterococcus Faecium Infections - Pipeline by Microbiotix, Inc., H1 2015 34
Enterococcus Faecium Infections - Pipeline by MicuRx Pharmaceuticals, Inc., H1 2015 35
Enterococcus Faecium Infections - Pipeline by Nabriva Therapeutics AG, H1 2015 36
Enterococcus Faecium Infections - Pipeline by NovaBay Pharmaceuticals, Inc., H1 2015 37
Enterococcus Faecium Infections - Pipeline by Novan, Inc., H1 2015 38
Enterococcus Faecium Infections - Pipeline by NovoBiotic Pharmaceuticals, LLC, H1 2015 39
Enterococcus Faecium Infections - Pipeline by Omnia Molecular Ltd., H1 2015 40
Enterococcus Faecium Infections - Pipeline by Oragenics, Inc., H1 2015 41
Enterococcus Faecium Infections - Pipeline by Sealife PHARMA GMBH, H1 2015 42
Enterococcus Faecium Infections - Pipeline by Sentinella Pharmaceuticals, Inc., H1 2015 43
Enterococcus Faecium Infections - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H1 2015 44
Enterococcus Faecium Infections - Pipeline by TAXIS Pharmaceuticals, Inc., H1 2015 45
Enterococcus Faecium Infections - Pipeline by Wockhardt Limited, H1 2015 46
Assessment by Monotherapy Products, H1 2015 47
Number of Products by Stage and Target, H1 2015 49
Number of Products by Stage and Mechanism of Action, H1 2015 51
Number of Products by Stage and Route of Administration, H1 2015 53
Number of Products by Stage and Molecule Type, H1 2015 55
Enterococcus Faecium Infections Therapeutics - Recent Pipeline Updates, H1 2015 106
Enterococcus Faecium Infections - Dormant Projects, H1 2015 124
Enterococcus Faecium Infections - Dormant Projects (Contd..1), H1 2015 125
Enterococcus Faecium Infections - Discontinued Products, H1 2015 126